Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Klingenberg (Hannover, Germany), J. Freise (Hannover, Germany), J. Fuge (Hannover, Germany), T. Welte (Hannover, Germany). Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM). 2144

Member's Comments

No comment yet.

Related content which might interest you: Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort Source: ERJ Open Res, 4 (1) 00121-2017; 10.1183/23120541.00121-2017 Year: 2018 Is pulmonary rehabilitation (PR) an effective therapy in lymphangioleiomyomatosis (LAM)? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Long-term sirolimus treatment in lymphangioleiomyomatosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Outcome of two patients with lymphangioleiomyomatosis without anti-estrogen therapy Source: Eur Respir J 2006; 28: Suppl. 50, 96s Year: 2006 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015